Gametocyte carriage in Plasmodium falciparum-infected travellers by Roberts, CH et al.
Roberts et al. Malaria Journal 2013, 12:31
http://www.malariajournal.com/content/12/1/31RESEARCH Open AccessGametocyte carriage in Plasmodium falciparum-
infected travellers
Catherine H Roberts1, Margaret Armstrong1, Ewa Zatyka1, Samuel Boadi2, Simon Warren1, Peter L Chiodini1,2,3,
Colin J Sutherland2,3 and Tom Doherty1*Abstract
Background: Gametocytes are the sexual stage of Plasmodium parasites. The determinants of gametocyte carriage
have been studied extensively in endemic areas, but have rarely been explored in travellers with malaria. The
incidence of gametocytaemia, and factors associated with gametocyte emergence in adult travellers with
Plasmodium falciparum malaria was investigated at the Hospital for Tropical Diseases in London.
Methods: Clinical, parasitological and demographic data for all patients presenting with P. falciparum malaria
between January 2001 and December 2011 were extracted from a prospective database. These data were
supplemented by manual searches of laboratory records and patient case notes.
Results: Seven hundred and seventy three adult patients with laboratory-confirmed P. falciparum malaria were
identified. Four hundred and sixty five (60%) were born in a country where malaria is endemic. Patients presented
to hospital a median of four days into their illness. The median maximum parasite count was 0.4%. One hundred
and ninety six patients (25%) had gametocytes; 94 (12%) on admission, and 102 (13%) developing during
treatment. Gametocytaemia on admission was associated with anaemia and a lower maximum parasitaemia.
Patients with gametocytes at presentation were less likely to have thrombocytopenia or severe malaria. Patients
who developed gametocytes during treatment were more likely to have had parasitaemia of long duration, a high
maximum parasitaemia and to have had severe malaria. There was no apparent association between the
appearance of gametocytes and treatment regimen.
Conclusions: The development of gametocytaemia in travellers with P. falciparum is associated with factors similar
to those reported among populations in endemic areas. These data suggest that acquired immunity to malaria is
not the only determinant of patterns of gametocyte carriage among patients with the disease.
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Gametocytes are the sexual stage of malaria parasites.
The generation of male and female gametes is necessary
for transmission to the mosquito vector where sexual re-
combination and generation of new haploid progeny
takes place. In acute infection with Plasmodium falcip-
arum, gametocytes arise seven to 15 days after the initial
patent parasitaemia and last for a mean of 6.4 (range
2.5–22) days in the circulation, longer than the typical
duration of asexual parasitaemia [1]. Factors associated* Correspondence: tom.doherty@uclh.nhs.uk
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reproduction in any medium, provided the orwith gametocyte production include the local intensity
of malaria transmission [2,3], the duration of infection,
presence of anaemia [4] and other haematological fac-
tors such as reticulocyte and lymphocyte counts [5].
Gametocytes are of increasing academic interest as
transmission-blocking interventions have been recog-
nized as potentially important tools for malaria control
and elimination [6-9].
Few data have been published on gametocyte carriage
among travellers with P. falciparum. Travellers represent
an interesting cohort for two reasons. First, they usually
present early in the natural history of their disease, and
second, they may have little immunity to malaria. This
provides an opportunity to analyse the effect of otherl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Population characteristics
Characteristics N = 773 (%)
Age, years, median (IQR) 38 (30–48)
Male 493 (63%)
UK born 208 (27%)
Admitted to hospital 758 (98%)
Time to presentation, days. median (IQR) 4 (2–7)
Median maximum parasite count (%), (IQR) 0.4% (0.05–2.0)
Severe malaria 364 (47%)
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impact of disease severity, on the likelihood with which
gametocytes are seen. In this study, factors associated
with gametocytaemia were assessed among a population
of adult travellers with P. falciparum malaria at the
Hospital for Tropical Diseases, London, UK.
Methods
The Hospital for Tropical Diseases is a tertiary referral hos-
pital in London. Patients may present directly, by general
practitioner referral or as a transfer from another hospital.
Demographic details of all patients admitted to the hospital
with falciparum malaria are prospectively collected into a
database. Patients treated as outpatients were identified by
reviewing laboratory records. Further data were collected
from laboratory and case note records. All patients diag-
nosed with P. falciparum between the beginning of January
2001 and end of December 2011 were included. The diag-
nosis of malaria was made by the UK’s Parasitology
Reference Laboratory using standard thick and thin films
which were, for those admitted, repeated daily until asexual
parasites were no longer seen. Severe malaria was defined
according to the unit’s guidelines: parasitaemia >2% and/or
the presence of complications [10]. Complications were
defined as: cerebral involvement, severe anaemia (Hb
<8.0 g/dl), renal failure (creatinine >265 mmol/L), pulmon-
ary oedema, hypoglycaemia, bleeding, disseminated intra-
vascular coagulation and acidosis. The cut-off for severe
malaria was a parasitaemia estimate of greater than 2%, by
microscopy. This conservative definition, the established
guideline for the study facility, is routinely deployed rather
than the WHO criteria of 4% parasitaemia. Associations be-
tween pairs of binary variables were tested for significance
using the c2 distribution. Continuous variables were com-
pared across binary categories using the Wilcoxon rank-
sum test. Multivariate logistic regression was performed on
those (binary) variables found significantly associated with
gametocyte carriage in the univariate tests. All statistical
analyses were performed in STATA (version 11; Timberlake
Consultants Limited, London, UK). The study was reviewed
and approved by the Audit and Research Committee at
HTD who stated that, as this was a retrospective case note
review, further formal ethical approval was not required.
Results
Eight hundred and twenty-two patients with laboratory-
confirmed P. falciparum malaria were identified. Forty-
nine of these were under the age of 18 years and were
excluded as their biological response to malaria differs
from adults. This left a total adult population of 773.
Demographics
Median age was 38 years and 63% were male. Four hun-
dred and sixty five (60%) had been born in a malaria-endemic country and may have had partial immunity to
the disease. Two hundred and sixty nine (34.8%) had
been born in a country without malaria transmission
and were assumed to be malaria-naïve (Table 1). The
remainder did not have a country of origin recorded.
Most (741, 96%) had travelled to Africa (Figure 1) and
had visited relatives in their country of origin (399, 52%)
(Figure 2).
Malaria infection
Relatively few patients had taken appropriate anti-
malarial prophylaxis (Table 2). Median time from onset
of symptoms to presentation was four days (IQR 2–7).
The median maximum parasite count was 0.4% (IQR
0.05–2.00). Most (758, 98%) were admitted to hospital.
A large proportion (364, 47%) had at least one marker of
severe disease. One hundred and ninety six patients
(25%) had gametocytes identified in peripheral blood
smears at one or more time points, 94 (12%) of these
harboured gametocytes at presentation while 102 (13%)
developed gametocytaemia during treatment.
Gametocytes at presentation
Patients who had gametocytaemia at presentation were
more likely to have been ill for longer, to be anaemic
and to have a normal platelet count (Table 2). In
addition, they were more likely to have a lower parasit-
aemia and less likely to have severe disease. The pres-
ence of gametocytes at presentation did not appear to be
influenced by anti-malarial chemoprophylaxis. There
was no discernible difference in the rate of gametocytae-
mia at presentation between those assumed to have
partial immunity and those who were malaria-naïve. The
time to presentation at a medical facility was no different
in naïve patients (Tables 3).
Multivariate logistic regression was performed with five
parameters significantly associated with the presence of
gametocytes at presentation (in decreasing order of appar-
ent strength of association): anaemia, thrombocytopenia,
asexual parasitaemia, duration of illness and severe anaemia
(Tables 2 and 3). The continuous variables asexual parasit-
aemia and duration of illness were converted to binary
Figure 1 Area of travel.
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each case (0.4% parasitaemia and 4 days, respectively).
Anaemia (OR 2.60, 95% CI 1.59 – 4.24; P <0.001),
thrombocytopenia (OR 0.50, 95% CI 0.30 – 0.83; P = 0.007)
and duration of illness (OR 1.77, 95% CI 1.10 – 2.82; P =
0.018) remained associated with the presence of gameto-
cytes at the time of presentation.
Gametocytes developing on treatment
Those who developed gametocytes during treatment were
more likely to have presented with a higher parasitaemia
and to have at least one marker of severe disease compared
to those who did not (Table 4). In addition, these patients
tended to have had asexual parasites for longer.
Most patients (643, 83%) were treated with quinine.
Artemisinin treatment was postulated to be associated with
a lower rate of gametocytaemia development post-treat-
ment. No evidence was found to support this among the 54
patients receiving an artemisinin-containing regimen (p =
0.226). However, this analysis was confounded by the fact
that patients treated with artemisinins were more likely to
be severe malaria cases (OR 2.80, 95% CI 1.42 - 5.81; p =
0.001) and those with severe malaria were independentlyFigure 2 Reason for travel.more likely to develop gametocytaemia following anti-
malarial treatment (Table 4).
Multivariate logistic regression was performed for the
parameters showing significant association with develop-
ment of gametocytaemia during treatment in univariate
analysis (Table 4). These were: duration of parasitaemia
(median cut-off: 4 days), anaemia, thrombocytopenia,
severe malaria and asexual parasitaemia. Of these
parameters, duration of parasitaemia (OR 1.48, 95% CI
1.25 – 1.75; P < 0.001) and the presence of any degree of
anaemia (OR 3.13, 95% CI 1.91 – 5.13; P < 0.001)
remained significantly associated with development of
peripheral gametocytaemia.
Discussion
Patients with gametocytes seen on their peripheral blood
film fall into two groups: those who have gametocytae-
mia at presentation and those who develop gametocytae-
mia during treatment. It was postulated that those who
have gametocytaemia at presentation would be more
likely to have been ill for longer; analysis of the data sup-
ported this, in both the duration of symptoms and the
haematological findings. These patients were more likely





P value of Z
score
P value (95% CI of
odds ratio)
N = 94 (12.8%) N = 639 (81.2%)
Duration of illness, days median (IQR) 5 (2-9) 4 (2-6) 0.0303 -
Length of stay in malarious country, days,
median (IQR)
29 (19-45) 24 (14-43) 0.3194 -
Maximum parasitaemia, % median (IQR) 0.15 (0.02-1.18) 0.4 (0.05-2.35) 0.0047 -
Anaemia n (%) 57 (61) 235 (36) - <0.0005 (1.361-
1.998)
Severe anaemia (Hb < 8 g/dl), n (%) 6 (6.4) 16 (2.5) - 0.045 (1.023-6.352)
Thrombocytopenia, n (%) 52 (55) 495 (76) - <0.0005 (0.593-
0.860)
Raised bilirubin, n (%) 43 (46) 306 (47) - 0.702 (0.756-1.208)
Severe malaria, n (%) 35 (37) 318 (49) - 0.039 (0.570-0.985)
Born in a malarious country, n (%) 59 (63) 390 (60) - 0.485 (0.743-1.121)
Prophylaxis taken, n (%) 17 (18) 140 (21.4) - 0.408 (0.524-1.300)
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likely to have thrombocytopenia (associated with acute
illness) than those who did not have gametocytes at
presentation. The data also suggest that despite the
chronicity of their illness, these patients were less un-
well; they tended to have a lower parasitaemia and fewer
of them had any markers of severe malaria.
There are two principal explanations for the ability of
some patients to tolerate malarial infection for longer
without becoming unwell. One is the use of partially ef-
fective infrequent anti-malarial chemoprophylaxis, which
may attenuate an infection without clearing it. The other
is previous exposure to malaria, which may induce
acquired immunity. There was no demonstrable associ-
ation between prophylaxis use (either complete or in-
complete) and gametocytaemia at presentation. It is well
documented that immunity to P. falciparum develops
among children who live in highly endemic areas and
survive repeated infections [11,12]. It may be reasonable
to assume that patients who grew up in malaria-endemicTable 3 Factors associated with gametocytaemia at presentat
Gametocytes at
presentation
N = 34 (12.6%)
Duration of illness, days median (IQR) 4 (2-8)
Maximum parasitaemia measured (%), median
(IQR)
0.3 (0.08 - 3.0)
Anaemia of any degree, n (%) 24 (71)
Severe anaemia (Hb < 8 g/dl), n (%) 2 (6)
Thrombocytopenia, n (%) 19 (56)
Raised bilirubin, n (%) 11 (32)
Severe malaria, n (%) 10 (29)
Prophylaxis taken, n (%) 9 (27)parts of the world and then migrated to the UK may
have some residual, but incomplete, immunity to the
disease and may therefore be more likely to tolerate a
subsequent infection. However, there was no discernible
relationship between being born in an endemic country
and having gametocytes at presentation.
Patients who have not grown up in an endemic area
are usually considered to be malaria-naïve. Intuitively,
this group may be considered at greater risk of severe
disease and less likely to tolerate malaria infection. How-
ever, this group had a similar rate of gametocytaemia at
presentation and were no more likely to have markers of
severe disease. In this group, factors associated with
gametocytaemia (severity of disease, anaemia, throm-
bocytopenia, etc) mirrored the findings from studies in
endemic areas. In a three-centre study, gametocytaemia
at presentation was seen in 35% of cases from Thailand,
37% of cases from The Gambia and 26% of cases from
Tanzania [13]. The rate of gametocytaemia reported here
for the naive group was lower than all of these estimatesion to hospital in malaria naïve patients
No gametocytes at
presentation
P value of Z
score
P value (95% CI of
odds ratio)
N = 235 (87.4%)
3 (2-6) 0.224 -
0.5 (0.02 - 1.75) 0.046 -
99 (40) - <0.0005 (1.29 - 2.18)
7 (3) - 0.383 (0.428-9.118)
198 (80) - 0.008 (0.490-0.899)
112 (45) - 0.132 (0.410-1.124)
139 (56) - 0.010 (0.292-0.846)
51 (21) - 0.524 (0.662-2.246)
Table 4 Factors associated with development of























Anaemia proportion 63.7% 31.4% <0.001**
Severe malaria, n (%) 60 (58.8) 260 (47.2) 0.017**
1 94 individuals who were gametocytaemic at presentation were excluded
from this analysis.
* Wilcoxon rank-sum test.
** c2 test.
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who did and did not have gametocytaemia at presenta-
tion in this group, suggesting that gametocytaemia at
presentation is not related to a delay in presentation to
medical services.
The data indicate that although previous exposure
may be important in determining which patients present
with gametocytaemia, this is not the full explanation. It
seems conceivable that some form of innate immunity
may also play a role in modulating the nature of the ill-
ness and the likelihood of gametocytes being present
early in the clinical disease. A number of factors have
been associated with the potential to protect against se-
vere complications of malaria, but contribute towards
anaemia, such as sickle cell trait [14]. However, what has
been observed here may be independent of such factors.
These findings are consistent with the limited published
data on immunity to circulating sexual stages of P. fal-
ciparum, which indicate that previous infection history
is a much less critical factor than it is for immune
modulation of asexual parasitaemia [9,12,15].
The emergence of circulating gametocytes in patients
receiving anti-malarial treatment has been associated
with the time taken to clear asexual parasites from the
peripheral circulation [16]. The data presented here cor-
roborate this, in that patients who had a longer period
of parasitaemia, who started with a higher parasitaemia
and who had severe malaria were more likely to develop
gametocytes. High parasitaemia and severe malaria are
not independent variables and, unsurprisingly, in multi-
variate analysis severe malaria did not remain signifi-
cantly associated with gametocyte emergence during
treatment. Artemisinin compounds clear parasitaemia
more rapidly than other anti-malarial drugs and are also
gametocytocidal [17,18]. It was anticipated thattreatment with artemisinins would reduce the prevalence
of gametocytaemia. This was not supported by the data,
although the analysis was confounded by the fact that
artemisinin therapy was more likely to be used for
patients with higher parasite counts.
Conclusion
No evidence was found that gametocyte carriage among
adult malaria patients in the UK was related to previous
exposure to malaria. This suggests that acquired immun-
ity alone is not the sole determinant of gametocyte
emergence in clinical cases.
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